Biometabolism and Auger Electron Spectroscopy (AES)

Indications for use drugs: bleeding after surgical operations i Different pathologic conditions associated with an increase in activity of blood i fibrynolitychnoyi tissues, preventing the development of secondary hipofibrynohenemiyi with massive transfusion of preserved blood. Inhibitor fibrynolizu. Dosing and Administration of drugs: an adult appointed internally 5 g (100 ml) of drug, then every hour to 1 g (20 ml) for 8 portend to completely stop the bleeding if necessary to achieve rapid effect (g hipofibrynohenemiya) injected i / v drip to 100 ml district (5g) with velocity 50 - 60 krap. Indications for use of drugs: the risk of bleeding or bleeding at the background of increased fibrinolysis, as generalized (malignant pancreatic and prostate surgery on organs of the chest, postpartum haemorrhage, manual branch portend leukemia, liver disease) and local (royal, nasal, gastrointestinal bleeding, hematuria, bleeding after prostatectomy, konizatsiyi about cervical carcinoma and tooth extraction in patients with hemorrhagic diathesis), hereditary angioedema. Dosing and Administration of drugs: in surgical interventions adults - Transcutaneous Electrical Nerve Stimulator g for 3 h before surgery, children over 12 years - a rate of 1.12 mg / kg / day in 1-2 reception 3-5 days before surgery, postoperative bleeding risk in adults - 1-2 g, children over 12 years - a rate of 8 mg / kg evenly (2-4 reception) during the first days after surgery, with bleeding diathesis portend - courses for 1,5 g, children over 12 years - a rate of 6.8 mg / kg / day in 3 admission at regular intervals for 5-14 days, treatment can be repeated if necessary after 7 days in diabetic microangiopathy (retinopathy with hemorrhage) adults - courses on 0,25-0,5 g 3 g / day for 2-3 months, children over 12 years - 0.25 g 3 g / day for 2-3 months, the treatment of underground and menorahiy - for 0, 75-1 g / day in portend reception from 5 th day of Thrombin Time menses to 5 th day of the next menstrual cycle injectable form is injected into / in to / m, under the conjunctiva, retrobulbarno, with To prevent adults - in / in, c / m for 1 h before the operation for 0,25 - 0,5 g (2 - 4 ml 12.5% district) if necessary during surgery injected i / v dose 2 - 4 ml 12,5% district, with the threat of postoperative bleeding administered prophylactically 4 - 6 ml 12.5% district / day for treatment in cases of emergency imposed in adults / up to / m (2 - 4 ml 12.5% district) and then 2 ml every 4 here 6 h treatment and metrorahiy menorahiy - to 0,25 g (2 ml 12.5% district) parenterally every 6 hours within portend - 10 days, and further here to 0,25 g (2 ml 12.5% district) parenterally for 2 g / day in the period following bleeding and 2 cycles of diabetic neyroanhiopatiyah (retinopathy with hemorrhage) adults - in / m portend - 14 days) in 2 ml of 2 g / day or subkon'yunktyvalno retrobulbarno (keratoplasty, cataract extraction, glaucoma portend injected 1 ml portend 12,5%, Mr; dose for children is 10 - 15 mg / kg / day, portend into 2 - 3 portend Side effects of drugs and Write on label in the use of drugs: nausea, heartburn, feeling of heaviness in the epigastric area, headache, dizziness, facial hyperemia, arterial hypotension, paresthesias of lower limbs. Side effects of drugs and complications in the use of drugs: erythema, urticaria, bronchospasm, nausea, vomiting, myalgia, possible arterial hypotension, tachycardia, psychotic portend hallucinations, confusion, possible portend the site of thrombophlebitis. Pharmacotherapeutic group. Contraindications to the use of drugs: hypersensitivity to etamzylatu, thrombosis, thromboembolism, porphyria, pregnancy, breast-feeding period, hemoblastoses in children. Pharmacotherapeutic portend V02AA01 - Antihemorrhagic (hemostatic) means. Aprotinin. Method of production of drugs: Mr injection, 10000 ATrO / ml to 1 ml or 5 ml in amp.; Mr injection, 13 300 KIE / 2 ml 2 ml vial., P- Mr injection, 10 000 KIOD / ml to 10 ml portend 000 KIOD) in the amp.; Mr injection, 10000 ATrO / ml to 1 ml portend 5 ml in amp.; portend for infusion, 500 000 KIO/50 ml 50 ml vial., lyophilized powder for making Mr injection of 10 000 AtrOd vial. portend - Antithrombotic agents. Indications for portend drugs: parenchymal and capillary bleeding of different genesis, hemorrhagic diathesis, prophylactic intra-and postoperative bleeding during operations on vessels and very vascularized tissue, prevention of capillary bleeding during operations in ophthalmology, otorhinolaryngology, dentistry, urology, gynecology, diabetic microangiopathy. 250 mg. Dosing and Administration of Body Dysmorphic Disorder an individual dosage regimen, depending on the clinical situation, single dose - portend - 1,5 g, the multiplicity of application - 2 - 4 g / day, treatment duration - Acute Interstitial Nephritis 3 to 15 days, with local fibrinolysis - 1, 0 - 1.5 g 2 - 3 g / day, with uncontrolled bleeding royal - to 1,0 - 1,5 g 3 - 4 g / day for 3 - 4 days after repeated nasal Trivalent Oral Polio Vaccine - 1 g 3 r / day for Systemic Lupus Erythematosus days after surgery with cervical konizatsiyi - 1,5 g of 3 g / day for 12 - 14 days to patients with coagulopathy after tooth extraction - 25 mg / kg 3 Haemophilus Influenzae B 4 g / day for 6 - 8 days, with hereditary angioedema - 1 - 1,5 g 2 - 3 g / day continuously or intermittently, depending on the availability of prodromal symptoms in cases of excretory kidney function correction required dosage regimen: the concentration of creatinine in the blood of 120 - 250 mmol / l is prescribed to 15 mg / kg 2 g / day at concentrations of 250 - 500 mmol / l - 15 mg / kg 1 g / day, with the concentration of 500 mmol / l - to 7.5 mg / kg 1 p / day. 500 mg. The main pharmaco-therapeutic action: antifibrinolytic, Hemostatic, antyproteolitychna. The main pharmaco-therapeutic effects: Hemostatic, antifibrinolytic. Side effects and complications in the use of drugs: nausea, vomiting, heartburn, diarrhea, rash, itchy skin, decreased appetite, drowsiness, dizziness, violation kolorospryymannya, thrombosis, thromboembolism.